Arcus Biosciences (RCUS) Accounts Payables: 2017-2025
Historic Accounts Payables for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $42.0 million.
- Arcus Biosciences' Accounts Payables rose 223.08% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.0 million, marking a year-over-year increase of 223.08%. This contributed to the annual value of $18.0 million for FY2024, which is 5.88% up from last year.
- Arcus Biosciences' Accounts Payables amounted to $42.0 million in Q3 2025, which was up 44.83% from $29.0 million recorded in Q2 2025.
- Arcus Biosciences' 5-year Accounts Payables high stood at $42.0 million for Q3 2025, and its period low was $10.0 million during Q4 2021.
- In the last 3 years, Arcus Biosciences' Accounts Payables had a median value of $17.0 million in 2023 and averaged $20.8 million.
- In the last 5 years, Arcus Biosciences' Accounts Payables spiked by 911.71% in 2021 and then crashed by 45.41% in 2023.
- Over the past 5 years, Arcus Biosciences' Accounts Payables (Quarterly) stood at $10.0 million in 2021, then surged by 100.00% to $20.0 million in 2022, then fell by 15.00% to $17.0 million in 2023, then climbed by 5.88% to $18.0 million in 2024, then skyrocketed by 223.08% to $42.0 million in 2025.
- Its Accounts Payables stands at $42.0 million for Q3 2025, versus $29.0 million for Q2 2025 and $22.0 million for Q1 2025.